Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma. The goal of this study was to evaluate the efficacy of firmonertinib neoadjuvant in patients with resectable stage II-IIIB EGFR-mutated non-small cell lung cancer (NSCLC) by major pathologic response (MPR).

Trial Details

NCT ID
NCT07622706
Phase
PHASE2
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Firmonertinib 80mg qd oral for 8 weeks.
  • Firmonertinib 160mg qd oral for 8 weeks.
  • Firmonertinib 80mg qd oral for 16 weeks.
  • Radical resection
  • firmonertinib adjuvant therapy
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Prior to the initiation of any study-related procedures, including examinations, sample collection, or analyses, written informed consent was obtai…
  • Male or female, aged \>=18 years;
  • Histologically or cytologically confirmed primary lung adenocarcinoma within 60 days prior to study entry.
  • Stage II-IIIB disease (AJCC 9th edition) confirmed by systematic imaging (contrast-enhanced chest/abdominal CT, brain CT/MRI, bone scan, or PET/CT)…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →